• Mashup Score: 0

    The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 122). Black patients are 76% more likely to be diagnosed w ith prostate cancer and 120% more likely to die from the disease than White

    Tweet Tweets with this article
    • Improving Genomic Testing Rates Among Black Patients With Prostate Cancer https://t.co/fvUGbnvcjV #pcsm #prostatecancer #genomics #HealthEquity #ASTRO23 #radonc

  • Mashup Score: 3

    PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed. RESULTS Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than

    Tweet Tweets with this article
    • RT @JCO_ASCO: 🧐 Pancreatic acinar cell carcinoma is a #BRCA2 HRD-related cancer: https://t.co/JqkXx1uEVE #PancSM #DNArepair #genomics @Cent…

  • Mashup Score: 7

    PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed. RESULTS Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than

    Tweet Tweets with this article
    • 🧐 Pancreatic acinar cell carcinoma is a #BRCA2 HRD-related cancer: https://t.co/JqkXx1uEVE #PancSM #DNArepair #genomics @CentralParkWMD @antoniomarraMD @EileenMOReilly

  • Mashup Score: 0

    In a Korean phase II trial (KCSG HN 15-16 TRIUMPH) reported in the Journal of Clinical Oncology, Keam et al described results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) using matched molecular targeted agents. In the multicenter trial, targeted next-generation sequencing was performed between October 2017 and August 2020 in 203 patients. Patients were assigned to treatment

    Tweet Tweets with this article
    • Personalized Biomarkers for Treatment of HNSCC https://t.co/glNJyjHffb #hncsm #headneckcancer #oncology #biomarkers #genomics